Andrew Matthews

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines”.

Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines

Cardio-Oncology(2024)10.1186/s40959-024-00275-5

N/A

0DataRank · unranked

7 citations

Andrew Matthews, Azin Vakilpour, Yu Min Kang, Bénédicte Lefebvre, Amanda M. Smith +6 more

A line in shifting sand: Can we define and target TP53 mutated MDS?

Seminars in Hematology(2024)10.1053/j.seminhematol.2024.10.009

N/A

0DataRank · unranked

2 citations

Andrew Matthews, Martin Carroll, Catherine Lai, Sarah Skuli

Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia

Haematologica(2024)10.3324/haematol.2024.285275

N/A

0DataRank · unranked

2 citations

Neeharika Prathapa, Noelle V. Frey, Saar Gill, Elizabeth O. Hexner, Ximena Bruno +13 more

Evolving racial/ethnic disparities in AML survival in the novel therapy era

Blood Advances(2025)10.1182/bloodadvances.2024014127

N/A

0DataRank · unranked

14 citations

Phyllis A. Gimotty, Andrew Matthews, Ronac Mamtani, Selina M. Luger, Elizabeth O. Hexner +15 more

Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response

Leukemia(2025)10.1038/s41375-025-02668-6

N/A

0DataRank · unranked

9 citations

A’ishah Bakayoko, Marisa Kruidenier, Bryan Manning, Paige Pammer, Akmal Salimov +33 more